Exclusive: Revalia Bio Raises $14.5M To ‘Revolutionize’ Drug Development With Human Data Trials

Revalia Bio Raises $14.5M Seed Round to Launch Human Data Trial Platform and Redefine Drug Development

NEW HAVEN, CT / ACCESS Newswire / September 4, 2025 / Revalia Bio Inc., announced a 14.5M seed funding round to support their launch of ‘Human Data Trials' - a new category of pre-clinical research that gives drug developers early,…

Exclusive: Revalia Bio Raises $14.5M To ‘Revolutionize’ Drug Development With Human Data Trials

New Haven, Connecticut-based Revalia Bio, a startup that helps companies test new therapies on human organs, has raised $14.5 million in seed funding, the company told Crunchbase News exclusively.

Revalia Bio Launches 'Human Data Trials' with $14.5M to Transform Drug Development

What You Should Know:  – Revalia Bio Inc., a new pre-clinical research company secures $14.5M in seed funding round to support the launch of its “Human Data Trials”. – The funding was co-led by America’s Frontier Fund and Sierra Ventures, with participation from Roger Ferguson, former Vice Chair of the U.S. Federal Reserve, and other existing investors. This brings Revalia’s total funding to $19.5M. A New Paradigm for Pre-Clinical Research The i…

Revalia Bio Raises $14.5M Seed Round

Revalia Bio, announced a 14.5M seed funding round to support their launch of ‘Human Data Trials’ – a new category of pre-clinical research that gives drug developers early, predictive insights from real, functional human organs. The round was co-led by America’s Frontier Fund and Sierra Ventures with participation from Roger Ferguson, former Vice Chair of the U.S. Federal Reserve and a member of the Board of Directors at Alphabet, and other exis…